Selenia Vitiello

First interim analysis of venetoclax real-world observational study on newly-diagnosed AML patients in Italy (VERO): Focus on patient and diseases characteristics and quality of life at baseline

Ivana Lotesoriere, Caterina Alati, lorenzo celona, Monia Lunghi et autres

Abstract Introduction The Venetoclax Real-World Observational study on effectiveness and treatment management in patients with Newly-Diagnosed (ND) Acute Myeloid Leukemia (AML) who are ineligible for intensive chemotherapy in Italy (VERO, NCT06058741) collects prospective real-world data on the effectiveness and safety of the …

it, us (code pays fourni par la source)

Complement Biomarkers for Tracking Breakthrough Hemolysis in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated with Last-Generation Complement Inhibitors

Luana Marano, Patrizia Ricci, Camilla Frieri, Eleonora Urciuoli et autres

Background After the introduction of complement inhibitors targeting C5 (eculizumab, ravulizumab), the field of PNH has been revolutionized by the development of proximal complement inhibitors targeting C3 (pegcetacoplan), factor D (danicopan) or factor B (iptacopan). Since they are able to prevent C3-mediated …

it (code pays fourni par la source)

Combination of DLI to Blinatumomab in Post- Transplant Molecular Relapse of Pediatric High- Risk ALL

Fabiana Cacace, Selenia Vitiello, Franceso Muriano, Daniela D’Angelo et autres

it (code pays fourni par la source)